Burrill Institutional Research Starts Stock Coverage on Omeros
October 15th, 2012
Investment analysts at Burrill Institutional Research began coverage on shares of Omeros Corp (NASDAQ: OMER) in a note issued to investors on Monday. The firm set an “outperform” rating and a $17.00 price target on the stock.
Burrill Research commented, "In addition to PharmacoSurgery™, Omeros is developing a novel drug for addiction, as well as an antibody targeting multiple indications. Both of these programs are in early stages of development, but conveniently, a significant fraction of their development costs are covered by external grants. Additionally, Omeros created a unique platform for the discovery of novel GPCR (G-Protein Coupled Receptor) targeted drugs. At a time when the discovery of new compounds for GPCRs has slowed down significantly, Omeros could become a respected partner for the pharma industry."